Jane Street
OREX

Jane Street’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Jane Street’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,150
Closed -$304K – 4683
2015
Q2 		$304K Buy
6,150
+20
+0.3% +$1.2K ﹤0.01% 2819
2015
Q1 		$480K Buy
6,130
+4,850
+379% +$301K ﹤0.01% 2095
2014
Q4 		$78K Buy
+1,280
New +$64.3K ﹤0.01% 2356

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jane Street's OREX Position: Q1 2016 in Review

Jane Street sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 4,972 shares — an estimated $86K sold.

Jane Street first reported a position in OREX in Q1 2014 and held it in 8 quarters. The position peaked at $864K in Q2 2014. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

  • Jane Street reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Jane Street sold 4,972 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $86K.
  • Jane Street first reported a position in Orexigen Therapeutics, Inc. in Q1 2014 and held it in 8 quarters.
  • Jane Street's Orexigen Therapeutics, Inc. position peaked at $864K in Q2 2014.
  • 104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on Jane Street's 13F filing for Q1 2016, filed 17 May 2016.